Akebia Therapeutics, Inc. (AKBA) Financial Statements (2023 and Earlier)

Company Profile

Business Address 245 FIRST STREET
CAMBRIDGE, MA 02142
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance Sheet (Statement of Financial Position) ($ in millions)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:150269148322318260139
Cash and cash equivalents1502291471057018750
Short-term investments  02172487389
Other undisclosed cash, cash equivalents, and short-term investments 40 0 00
Receivables512739173434 
Inventory, net of allowances, customer advances and progress billings3861116114   
Inventory3861116114   
Other undisclosed current assets3315716622
Total current assets:272371310468358296141
Noncurrent Assets
Operating lease, right-of-use asset342729
Property, plant and equipment79108431
Intangible assets, net (including goodwill)163199346383   
Goodwill55555555   
Intangible assets, net (excluding goodwill)108144291328   
Other noncurrent assets503876137211
Other undisclosed noncurrent assets      0
Total noncurrent assets:254273462528642
TOTAL ASSETS:526644771997364300143
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities138172168194593212
Accounts payable34413943722
Accrued liabilities104131129151523010
Deferred revenue211540
Debt98  15   
Deferred revenue and credits8582 
Contract with customer, liability57
Total current liabilities:25618720826614411412
Noncurrent Liabilities
Long-term debt and lease obligation34121103    
Long-term debt, excluding current maturities 9676    
Operating lease, liability342528
Liabilities, other than long-term debt1048663881011180
Deferred revenue and credits101118 
Deferred revenue212533
Contract with customer, liability56
Deferred rent credit   3
Other liabilities83613030000
Other undisclosed noncurrent liabilities55227   
Total noncurrent liabilities:193209168951011180
Total liabilities:44939737636124523212
Stockholders' equity
Stockholders' equity attributable to parent7624839563611968131
Common stock0000   
Treasury stock, value      (0)
Additional paid in capital1,5371,4251,1891,151494365293
Accumulated other comprehensive income (loss)00 (0)(0)(0)(0)
Accumulated deficit(1,460)(1,178)(794)(514)(374)(297)(161)
Total stockholders' equity:7624839563611968131
TOTAL LIABILITIES AND EQUITY:526644771997364300143

Income Statement (P&L) ($ in millions)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Revenues2142953352081782 
Revenue, net1782 
Cost of revenue(153)(296)(145)(8)   
Cost of goods and services sold(153)(180)(109)(6)   
Gross profit:60(1)1902001782 
Operating expenses(326)(376)(476)(378)(258)(138)(62)
Operating loss:(265)(376)(286)(178)(80)(136)(62)
Nonoperating income (expense)22(1)0010
Investment income, nonoperating     1 
Other nonoperating income (expense)22(1)00(0)0
Loss from continuing operations before equity method investments, income taxes:(263)(375)(287)(178)(80)(136)(61)
Other undisclosed income (loss) from continuing operations before income taxes(20)(9)16   
Loss from continuing operations before income taxes:(283)(383)(286)(172)(80)(136)(61)
Income tax benefit  728   
Net loss:(283)(383)(280)(144)(80)(136)(61)
Other undisclosed net income attributable to parent    3 1
Net loss available to common stockholders, diluted:(283)(383)(280)(144)(77)(136)(61)

Comprehensive Income ($ in millions)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Net loss:(283)(383)(280)(144)(80)(136)(61)
Comprehensive loss:(283)(383)(280)(144)(80)(136)(61)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(0)0002(0)0
Comprehensive loss, net of tax, attributable to parent:(283)(383)(279)(143)(77)(136)(61)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: